Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 153-159

  Restrepo, M I ^a,b,c   Mortensen, E M ^a,b,c   Waterer, G W ^e   Wunderink, R G ^d   Coalson, J J ^b   Anzueto, A ^b,c  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antibiotics; Community acquired pneumonia; Outcomes; Sepsis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TEACHING HOSPITAL; THORAX RADIOGRAPHY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58849166805     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00054108     Document Type: Article

References (30)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
3. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
4. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005; 53: 1-48.
5. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994; 9: 140-152.
6. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
7. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48: 93-99.
8. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of communityacquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
9. Parnham MJ, Culic O, Erakovic V, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 2005; 517: 132-143.
10. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54: 21-28.
11. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-444.
12. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a b-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-395.
13. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131: 466-473.
14. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-1842.
15. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 589-593.
16. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004; 32: 625-631.
17. Garcia Vazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24: 190-195.
18. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420-1426.
19. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726-731.
20. Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 1493-1498.
21. Cazzola M, Saltini C. Novel approaches to the treatment of bacterial lower respiratory tract infections: introduction. Respiration 2005; 72: 7-8.
22. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18: 125-131.
23. Bone RC. Why sepsis trials fail. JAMA 1996; 276: 565-566.
24. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064.
25. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
26. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. 11th Informational Supplement. Wayne, National Committee for Clinical Laboratory Standards, 2001.
27. Stone RA, Obrosky DS, Singer DE, Kapoor WN, Fine MJ. Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. Med Care 1995; 33: Suppl. 4, AS56-AS66.
28. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
29. Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator associated pneumonia. Clin Infect Dis 2008; 46: 1157-1164.
30. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2006; 10: R8.